Levodopa-Carbidopa

• Levodopa-Carbidopa

• Sinemet

Classification:

• Antiparkinson

Mechanism of Action:

• Combination of L-Dopa with a peripheral DOPA decarboxylase inhibitor (DDCI) such as Carbidopa allows for smaller doses of L-dopa to be administer to the patient as this combination inhibits early PNS conversion of L-dopa into dopamine.
• L-Dopa crosses the BBB but Carbidopa cannot so conversion takes place in cerebral circulation thus requiring less dosage and minimizes side effects from larger dosages

Indications:

• Parkinson’s Disease

• Compendium of Pharmaceuticals and Specialties (CPS)